Genedrive Plc (Genedrive) formerly Epistem Holdings Plc specializes in the development of point-of-care molecular diagnostic platforms. The company's major activities include the creation of innovative tests for various clinical indications such as genotyping, pathogen detection, and infectious disease detection. The company's major products include the Genedrive MT-RNR1 ID kit, used for detecting antibiotic-induced hearing loss in neonates, and the Genedrive CYP2C19 ID kit, a rapid point-of-care test for CYP2C19 genotyping. The company's products are primarily used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. The company provides its products in North America, Asia Pacific, Europe, Middle East and Africa (EMEA) region through its distribution partners. Genedrive is headquartered in Manchester, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Genedrive Plc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Genedrive Plc Company Overview
Genedrive Plc Company Snapshot
Genedrive Plc Pipeline Products and Ongoing Clinical Trials Overview
Genedrive Plc – Pipeline Analysis Overview
Business Description
Genedrive Plc - Key Facts
Genedrive Plc - Major Products and Services
Genedrive Plc Pipeline Products by Development Stage
Genedrive SARS-CoV-2 POC Kit - Version 2 Product Overview
Genedrive Plc - Key Competitors
Genedrive Plc - Key Employees
Genedrive Plc - Key Employee Biographies
Genedrive Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Genedrive Plc, Recent Developments
May 24, 2024: genedrive : Initial Orders of the Genedrive MT-RNR1 Products for New Sites in the UK
Apr 24, 2024: Genedrive enters into a Clinical Trial Agreement with a leading multi-state physician organisation for clinical research studies of the Genedrive MT-RNR1 Product Range in the USA
Apr 03, 2024: NICE Launches Second Consultation on Genetic Testing to Guide Treatment after a Stroke
Apr 03, 2024: NICE recommends the Genedrive CYP2C19-ID Kit
Feb 19, 2024: Genedrive : NICE Early Value Assessment update
Dec 20, 2023: Genedrive : Initial Overseas Orders of the Genedrive MT-RNR1 ID Kit
Dec 04, 2023: MT-RNR1 ID Kit Adopted for Routine Use in Brighton
Sep 28, 2023: Genedrive to Benefit From c£1.2m Grant Awarded for the Validation of the Genedrive CYP2C19 ID Kit
Sep 06, 2023: Genedrive : UKCA Marking Achieved for New Genedrive CYP2C19 Test
Jun 16, 2023: Multi-Partner Grant Awarded for the Validation of Genedrive CYP2C19 ID Kit in Time Critical NHS Settings